Page 2
Janssen, the Pharmaceutical Companies of Johnson & Johnson, announced today that Darzalex ®(daratumumab) in combination with lenalidomide and dexamethasone (DRd) has been reimbursed in Ireland for the treatment…
IRELAND’S HSE APPROVES LILLY’S ABEMACICLIB IN COMBINATION WITH ENDOCRINE THERAPY FOR ADJUVANT TREATMENT OF PEOPLE WITH HR+, HER2- EARLY BREAST CANCER AT HIGH-RISK OF RECURRENCE Abemaciclib in combination…
AbbVie has announced that the Irish health authorities have approved reimbursement of PRODUODOPA® (foslevodopa/foscarbidopa) for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia…
End-of-trial data show 79.7% efficacy in participants aged 50 years and over during long-term follow-up, six to 11 years after vaccination1 Vaccine efficacy remained high for each year…
Eli Lilly and Company announced that the European Commission (EC) granted marketing authorization (MA) on 19 April 2024 for tirzepatide (Mounjaro®) solution for injection in a multi-dose KwikPen®…
Following a 30-year joint venture, Sandoz, the world’s largest generics and biosimilars company, has acquired full ownership of Rowex. Rowex has been operating in Bantry, Co. Cork, since…
Dostarlimab plus chemotherapy is the only immuno-oncology combination to show statistically significant and clinically meaningful overall survival (OS) in the overall population 31% reduction in risk of death…
Astellas Pharma recently announced results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for enfortumab vedotin in combination with pembrolizumab versus chemotherapy. The combination improved…
The International Canoe Federation’s (ICF) Women’s Paddlesports Symposium, hosted by Canoeing Ireland concluded with participants from 34 countries agreeing to actions to create equity in sport. The two-day inaugural…
Talquetamab, the first bispecific antibody targeting GPRC5D, showed an overall response rate of more than 70 percent with durable responses, including responses achieved by over 60 percent of…
You’re all caught up.
